Research programme: bupropion metabolite - Biocopea LimitedAlternative Names: SD281
Latest Information Update: 16 Jul 2016
At a glance
- Originator Sosei
- Developer Biocopea
- Class Small molecules
- Mechanism of Action Interleukin 12 modulators; Tumour necrosis factor alpha modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammation